RSS
Phase IIb study
FDA accepts IND application allowing InflaRx to initiate Phase IIb study
The FDA has accepted an IND application by biopharmaceutical company, InflaRx, which will enable the company to initiate a Phase IIb study evaluating the efficacy and safety of IFX-1 in patients with moderate or severe Hidradenitis Suppurativa. Read more
